Gamma-Carboline Composition for Selective 5-HT2A Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional compounds with strong serotonin receptor, serotonin transporter (SERT), and/or dopamine D2 receptor activities to treat a range of central nervous system disorders and psychiatric conditions, including anxiety, psychosis, schizophrenia, sleep disorders, and mood disorders, while minimizing side effects associated with conventional treatments.
Innovation Solution
The development of a novel compound, referred to as Compound 1, which exhibits potent affinity for serotonin receptors (5-HT2A, 5-HT2B), serotonin transporters (SERT), dopamine receptors (D2), sodium channels, and norepinephrine transporters, available in free or pharmaceutically acceptable salt forms, including toluenesulfonic acid addition salts, and formulated for sustained or delayed release through polymeric matrices or osmotic-controlled oral delivery systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sedative-hypnotic agents (e.g., benzodiazepines) are used to treat sleep disorders, then sedation effect is achieved, but side effects occur including drug dependency, muscle hypotonia, weakness, headache, blurred vision, vertigo, nausea, vomiting, epigastric distress, diarrhea, joint pains, and chest pains
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of gamma-carboline compounds through specific substitutions at positions 1, 3, and 4 of the core structure. These structural parameter changes result in compounds that selectively antagonize 5-HT2A receptors with minimal effect on dopamine D2 receptors, thereby achieving sedation through a different pharmacological mechanism that avoids the side effects associated with conventional sedative-hypnotic agents
Solution Approach 2:
The patent employs local quality by introducing specific substituent groups at particular positions (1, 3, and 4) of the gamma-carboline core structure. Each substitution is strategically placed to optimize 5-HT2A receptor selectivity while minimizing interactions with other receptor systems, particularly dopamine D2 receptors, thereby achieving localized pharmacological selectivity that reduces unwanted side effects
2Reliability
If high dose compounds are used to achieve strong serotonin receptor and dopamine receptor activity, then therapeutic effect is improved, but side effects associated with high occupancy of dopamine D2 pathways increase
Solution Approach 1:
The patent applies parameter changes by optimizing the substituent groups at positions 1, 3, and 4 of the gamma-carboline structure to achieve high 5-HT2A receptor affinity (Ki values of 1-100 nM) while maintaining low affinity for dopamine D2 receptors. This differential affinity profile allows therapeutic doses to selectively target serotonin receptors without significantly occupying dopamine pathways, thereby achieving strong therapeutic effects while minimizing dopamine-related side effects
Solution Approach 2:
The patent uses the 5-HT2A receptor as an intermediary mechanism to achieve therapeutic effects without directly targeting dopamine D2 receptors. By designing compounds that primarily act as 5-HT2A antagonists, the patent indirectly addresses conditions like sleep disorders and psychosis through serotonin pathway modulation, avoiding the need for high dopamine D2 occupancy and its associated side effects
Data Source
AI summary
The invention relates to a particular substituted heterocycle fused gamma-carboline, the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.